Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 6Phase 1 5Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 4Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Carcinoma, Renal Cell 2Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Microsatellite Instability 1Lymphoma, Large B-Cell, Diffuse 1Kidney Neoplasms 1Kidney Diseases 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Leucovorin 22Fluorouracil 22Gemcitabine 21Capecitabine 21Paclitaxel 20Docetaxel 20Irinotecan 15Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × avelumab × Clear all
NCT02625610 2022-06-09

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

EMD Serono

Phase 3 Completed
499 enrolled 22 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡